AN ANTI-ALLERGIC DRUG TARGETING PI3K DELTA

DESCRIPTION
PI3Kinase delta is an enzyme expressed by few cell types including human basophils, a type of white blood cell involved in allergy.
We have developed an inhibitor of PI3Kinase delta which potently inhibits degranulation of stimulated normal human basophils and protects mice developing albumininduced allergic asthma. This treatment was well tolerated when administred over a period of several weeks and was associated with a significant
reduction in the pulmonary cellular inflammatory infiltrate.

STAGE OF DEVELOPMENT
The PI3Kinase inhibitor which we have developed has shown significant preclinical activity with normal human stimulated basophils and in a preclinical mouse models of allergic asthma. Non regulatory chronic exposure for periods up to 4 weeks showed no sign of toxicity. Future development will include regulatory preclinical toxicity before proceeding to a first in man study in patients with severe asthma.

ADVANTAGES / NOVELTY
• Targeted therapy
• Excellent tolerance
• Bioavailable by oral or intravenous route
• Simple and low-cost synthesis

APPLICATIONS
• Our primary indication is severe asthma, in particular in patients relying on large daily doses of steroids and/or refractory to therapy. Efficacy will be measured by spirometric examinations.
• Secondary indications include other manifestation of allergy, including cutaneous and mucosal manifestations.

INTELLECTUAL PROPERTY
Patent pending in PCT
Priority date: April 5th, 2013 (FR1353091)

COLLABORATION TYPE
PULSALYS looks for industrial partners and offers to grant patent license.

CONTACT
Daphné THOMAS
Tech Transfer Officer
Tel. +33 (0)4 26 23 56 78
daphne.thomas@pulsalys.fr